Monitoring of post-transplant remission of childhood malignancies: Is there a standard?

Bone Marrow Transplantation

Volumn 42, Issue SUPPL. 2, 2008, Pages

  Bader, P ^a   Willasch, A ^a   Klingebiel, T ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; LEUKOSIALIN;

ACUTE LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; DONOR LYMPHOCYTE INFUSION; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALIGNANT NEOPLASTIC DISEASE; MICROCHIMERISM; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TRANSPLANTATION TOLERANCE; TREATMENT RESPONSE;

ACUTE DISEASE; ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; LEUKEMIA; MALE; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RISK FACTORS; TRANSPLANTATION CHIMERA;

EID: 55749098361     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.280     Document Type: Review

References (23)

1. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
2. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
3. Bader P, Hoelle W, Klingebiel T, Handgretinger R, Benda N, Schlegel PG et al. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: The impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 1997; 19: 69 7-702.
4. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-417.
5. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35: 107-119.
6. Chung NG, Buxhofer-Ausch V, Radich JP. The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens 2006; 68: 371-385.
7. Roux E, Abdi K, Speiser D, Helg C, Chapuis B, Jeannet M et al. Characterization of mixed chimerism in patients with chronic myeloid leukemia transplanted with T-cell-depleted bone marrow: Involvement of different hematologic lineages before and after relapse. Blood 1993; 81: 243-248.
8. Roux E, Helg C, Chapius B, Jeannet M, Roosnek E. Mixed chimerism after bone marrow transplantation and the risk of relapse. Blood 1994; 84: 4385-4386.
9. Ramirez M, Diaz MA, Garcia-Sanchez F, Velasco M, Casado F, Villa M et al. Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia. Bone Marrow Transplant 1996; 18: 11 61-1165.
10. Formankova R, Sedlacek P, Krskova L, Rihova H, Sramkova L, Star J. Chimerism-directed adoptive immunotherapy in prevention and treatment of post-transplant relapse of leukemia in childhood. Haematologica 2003; 88: 117-118.
11. Fernandez-Aviles F, Urbano-Ispizua A, Aymerich M, Colomer D, Rovira M, Martinez C et al. Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood. Leukemia 2003; 17: 613-620.
12. Gorczynska E, Turkiewicz D, Toporski J, Kalwak K, Rybka B, Ryczan R et al. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: A report of 14 children. Bone Marrow Transplant 2004; 33: 211-217.
13. Suttorp M, Schmitz N, Dreger P, Schaub J, Loffler H. Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms. Leukemia 1993; 7: 679-687.
14. Guimond M, Busque L, Baron C, Bonny Y, Belanger R, Mattioli J et al Relapse after bone marrow transplantation: Evidence for distinct immunological mechanisms between adult and paediatric populations. Br J Haematol 2000; 109: 130-137.
15. Barrios M, Jimenez-Velasco A, Roman-Gomez J, Madrigal ME, Castillejo JA, Torres A et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003; 88: 801-810.
16. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696-1706.
17. Knechtli CJ, Goulden NJ, Hancock JP, Harris EL, Garland RJ, Jones CG et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998; 102: 860-871.
18. Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002; 16: 1668-1672.
19. Gabert J, Beillard E, van der Velden V, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program. Leukemia 2003; 17: 2318-2357.
20. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013-1034.
21. Thiede C, Lutterbeck K, Oelschlagel U, Kiehl M, Steudel C, Platzbecker U et al. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells. Ann Hematol 2002; 81: S27-S28.
22. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15 1976-1985.
23. Winiarski J, Mattsson J, Gustafsson A, Wester D, Borgstrom B, Ringden O et al. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation. Pediatr Transplant 1998; 2: 150-156.